3SCHMIEGELOW K,GLOMSTEIN A,KRISTINSSON J,et al.Influence of circadian schedule and of food on the pharmacokinetics of methotrexate and on relapse risk in chindhood acute lymphoblastic leukemia[J].Pediatr Hematol Oncol,2007,19(12):102-109.
4MATLOUB Y,LINDEMULDER S,Linda C S,et al.Intrathecal triple therapy decreases central nervous system reeapse but fails to improve enent-free survival when compared with intrathecal methotrexate:results of the Children's Cancer Group(CCG)1952 study for standardrisk acute lymphoblastic leukemia,reported by the Children's Oncology Group[J].Blood,2006,108(6):1165-1173.
5PINDEL D,WOO S.Prevention and treatment of menin-gealleuk-emia in children[J].Blood,1994,84(4):335.
6ESTLIN E J,YULE S M,LOWIS S P,et al.Consolidation therapy for childhood acute lymphoblastic leukemia:clinical and cellular pharmacology of cytosine arabinoside,epipodophyllotoxins and cyclophosphamide[J].Cancer Treat Rev,2001,27:339-350.
7WELCH J C,LENNARD L,MORTON G C A,et al.Pharmacokinetics of mercaptopurine:plasma drug and red cell metabolite concentrations after an oral dose[J].Ther Drug Monit,1997,19(5):382-385.
9TOYODA Y,MANABE A,TSUCHIDA M,et al.Six months of maintenance chemotherapy alter intensified treatment for acute lymphoblastic leukemia of childhood[J].J Clin Oncol,2000,18(3):1508-1516.
10KAGER L,CHEOK M,YANG W T,et al.Folate pathwaygene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexated pharmacodynamics[J].J Clin Invest,2005,115(1):110-117.
